However, in contrast to the dramatic improvement achieved by EGFR inhibitors in the survival of patients with NSCLC harboring activating EGFR mutations, EGFR inhibitors still have only limited roles in the clinical management of patients with NSCLC lacking such mutations, which constitutes the majority of NSCLC cases [5, 6, 7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.